Skip to content

NASDAQ · large · thesis board

REGN Regeneron

Fully human antibody / CD3 bispecific oncology platform

View race

Thesis

Editorial summary — not a primary filing

Antibody engine with expanding myeloma bispecific and solid-tumor oncology optionality.

Next gate

2026-12-14Company-guidedPh3 readout

Myeloma bispecific Phase 3

123 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~28 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~988d)100%
Days to gate (123d)12%
Show math

$13.0B cash ÷ $400M/mo burn ≈ 988 days. Source: curated SEC quarter figures.

Cash $13.0B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
JNJApprovedokLEGNApprovedokBMYApprovedok

Risks

  • Eylea competition
  • Oncology execution
  • BD
  • Policy

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05137054as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01